.jpg)
1 hour ago
3
Article content
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“Circular”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“Meeting”).
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Detailed results of the vote for the election of directors held at the Meeting are set out below:
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
| Nominee | Votes FOR | % of Votes FOR | Votes WITHHELD/ABSTAINED | % of Votes WITHHELD/ABSTAINED |
| Aras Azadian | 57,104,246 | 98.744% | 726,517 | 1.256% |
| Giancarlo Davila Char | 57,100,638 | 98.737% | 730,125 | 1.263% |
| Michael Kott | 57,100,638 | 98.737% | 730,125 | 1.263% |
| Ozgur Kilic | 57,100,584 | 98.737% | 730,179 | 1.263% |
| Lisa McCormack | 57,100,525 | 98.737% | 730,238 | 1.263% |
Article content
At the Meeting, the Company’s shareholders also approved: (i) fixing the number of directors for the ensuing year at five and empowering the board of directors of the Company to adjust such number between shareholder meetings by way of resolution in accordance with the Company’s constating documents; (ii) the reappointment of Ramirez Jimenez International CPAs, as the Company’s auditors for the ensuing year and authorized the board of directors to fix the auditors’ remuneration; and (iii) the unallocated awards and ratification awards under the Company’s Omnibus Long-Term Incentive Plan, the full text of which was set forth in the Circular.
Article content
Article content
About Avicanna:
Article content
Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products.
Article content
- Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
Article content
- Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
English (US)